Adaptive Biotechnologies Corporation Common Stock(ADPT)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $12.00 – $29.96
- YTD
- +83.41%
- IV Rank (30D)
- 99.78
- Straddle Price
- $3.52
- P/C Vol Ratio
- 1.04
- Market Cap
- $4.7B
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.52 |
| Cost of Equity (CAPM) | 13.32% (VRP-adj) |
| WACC | 12.62% |
| Volatility Risk Premium | +190.1pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 5 years explicit + fade |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -44.7% |
| Book / Price | 3.2% |
| Gross Margin (TTM) | 75.6% |
| FCF Margin (TTM) | -7.8% |
| Debt / Equity | 2.22 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $24.84 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $26.06 |
| Bollinger Width / SMA20 | 106.3% (drives anchor stability) |
| Net Debt | $0.2B |
| Market Cap | $5B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 38.4× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 136.3× · 4 peers |
| Peer P/B | $7.97 | 19% | median 8.3× · 7 peers |
| Peer P/S | $32.14 | 19% | median 16.4× · 8 peers |
| Market Anchor (SMA50) | $24.84 | 63% | stability 66% (BB-width) |
| Options Expected (B-L 30d) | $29.65 | 0% | 5 strikes · skew +0.32 |
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
- Exchange
- XNAS
- Market Cap
- $4.7B
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company ha…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +1.92% | 6 |
| Feb | -4.18% | 6 |
| Mar | -2.89% | 6 |
| Apr | -8.54% | 6 |
| May | +7.10% | 6 |
| Jun | +12.65% | 6 |
| Jul | +10.97% | 6 |
| Aug | -3.07% | 6 |
| Sep | -0.70% | 6 |
| Oct | -2.38% | 5 |
| Nov | +4.84% | 5 |
| Dec | +1.81% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 7/10)
Key Drivers:
- Negative news sentiment
- Bearish momentum indicators
- High volatility
Primary Risks:
- Oversold RSI
- Low institutional interest
Investment Thesis: ADPT is trading in a downtrend, driven by negative news sentiment and bearish momentum signals. The stock has high volatility, making it a higher-risk investment.
Recent News Sentiment Impact: The recent news headlines are overwhelmingly negative, with several executives selling shares under 10b5-1 plans and tax-driven share sales. This negative news sentiment is likely contributing to the stock's downtrend.
Technical Analysis
Trend Direction:
- Short-term: BEARISH
- Medium-term: BEARISH
- Long-term: NEUTRAL
Support/Resistance Levels:
- SMA 20: $15.34 (resistance)
- SMA 50: $16.51 (resistance)
- Upper Bollinger Band: $17.43 (resistance)
Momentum Signals:
- RSI (14): 32.73 (oversold)
- MACD: -0.81 / Signal: -0.26 / Histogram: -0.55 (bearish)
- Stochastic %K: 15.73
- Stochastic %D: 15.36
Volume Analysis:
- Volume SMA 20: 1682602.68
- On-Balance Volume (OBV): 28951816.77
- Volume Rate of Change: N/A%
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines are mostly negative, with several executives selling shares under 10b5-1 plans and tax-driven share sales.
Sentiment Assessment: The overall sentiment is NEGATIVE, driven by the recent news headlines.
Catalyst Identification: There are no near-term catalysts that could significantly impact the stock's price.
Market Narrative: The market narrative is bearish, with negative news sentiment driving the downtrend.
Risk & Volatility Assessment
Risk Metrics:
- Beta: 1.39 (high risk)
- Alpha: 0.60
- Correlation: 0.36
- Stock Volatility: 0.73
Options Market Signals: The options market is pricing a $3.27 move by expiration, indicating high volatility.
Downside Protection: The stock has strong technical support at the SMA 20 and SMA 50 levels.
Market Context & Positioning
Sector Performance: ADPT is underperforming its sector, with a negative correlation.
Institutional Activity: There is low institutional interest in the stock, suggesting limited buying pressure.
Correlation Analysis: The stock has a high beta relative to the market, indicating a strong inverse correlation.
Relative Valuation: The stock is trading at the lower end of its historical range, making it relatively cheap.
Key Levels & Action Items
Critical Price Levels:
- SMA 20: $15.34 (resistance)
- SMA 50: $16.51 (resistance)
Breakout/Breakdown Levels:
- Upper Bollinger Band: $17.43 (resistance)
Time-Sensitive Catalysts: There are no near-term catalysts that could significantly impact the stock's price.
Risk Management: Stop-loss levels should be set at the SMA 20 and SMA 50 levels to limit potential losses. Position sizing considerations should prioritize caution due to high volatility.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-11-07 | After-Close | 18.35% | 6.79% | 0.37x | Within |
| 2025-02-11 | Pre-Market | 33.85% | 0.26% | 0.01x | Within |
| 2025-05-01 | Pre-Market | 13.91% | 0.34% | 0.02x | Within |
| 2025-08-05 | After-Close | 23.53% | 5.79% | 0.25x | Within |
| 2025-11-05 | Pre-Market | 24.82% | 3.96% | 0.16x | Within |
| 2026-01-12 | Pre-Market | 12.57% | 15.75% | 1.25x | Exceeded |
| 2026-05-05 | Pre-Market | 22.34% | 5.87% | 0.26x | Within |
| 2026-07-29 | Pre-Market | 20.43% | 0.18% | 0.01x | Within |
- IV Rank (30D)
- 99.78
- IV Rank (7D)
- 99.78
- Avg IV
- 281.5%
- Straddle (30D)
- $3.52
- Straddle (7D)
- $3.52
- P/C Volume
- 1.04
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
- Beta (1Y vs SPY)
- 1.67
- Correlation (SPY)
- 31.8%
- R²
- 0.10
- Ann. Volatility
- 68.0%
- SPY Volatility
- 13.0%
High volatility - stock moves more than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | UBS Group AG Custodian | $61.39M | 42.17% | 2026-06-30 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $42.28M | 29.05% | 2026-06-30 |
| 3 | TORONTO DOMINION BANK | $38.61M | 26.52% | 2026-06-30 |
| 4 | CITADEL ADVISORS LLC Custodian | $1.65M | 1.13% | 2026-06-30 |
| 5 | JANE STREET GROUP, LLC Custodian | $1.16M | 0.80% | 2026-06-30 |
| 6 | SIMPLEX TRADING, LLC Custodian | $463.32K | 0.32% | 2026-06-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $4.29K | <0.01% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $669.24K | 96.89% | 2026-06-30 |
| 2 | SIMPLEX TRADING, LLC Custodian | $21.45K | 3.11% | 2026-06-30 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | FRANCIS LO | Chief People Officer | Mixed | −9,846 | $19.23 | -$2.23M | EDGAR |
| 2026-09-17 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell (S) | −1,195 | $27.00 | -$32.3K | EDGAR |
| 2026-09-02 | KATEY EINTERZ OWEN | Director | Gift (G) | −12,539 | — | EDGAR | |
| 2026-08-28 | KATEY EINTERZ OWEN | Director | Sell (S) | −9,615 | $26.00 | -$250.0K | EDGAR |
| 2026-08-20 | ROBERT HERSHBERG | Director | Mixed | −15,664 | $18.46 | -$653.4K | EDGAR |
| 2026-08-19 | PETER M NEUPERT | Director | Mixed | −109,690 | $23.13 | -$3.04M | EDGAR |
| 2026-08-19 | CHAD M ROBINS | CEO and Chairman | Mixed | — | $15.68 | -$10.95M | EDGAR |
| 2026-08-12 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell (S) | −3,000 | $25.00 | -$75.0K | EDGAR |
| 2026-08-03 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell (S) | −1,299 | $24.00 | -$31.2K | EDGAR |
| 2026-07-23 | HARLAN S ROBINS | Chief Scientific Officer | Mixed | −207,600 | $16.27 | -$8.91M | EDGAR |
| 2026-07-20 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell (S) | −5,000 | $23.00 | -$115.0K | EDGAR |
| 2026-07-17 | FRANCIS LO | Chief People Officer | Mixed | — | $15.75 | -$1.45M | EDGAR |
| 2026-07-07 | HARLAN S ROBINS | Chief Scientific Officer | Sell (S) | −386,240 | $22.01 | -$8.50M | EDGAR |
| 2026-07-06 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell (S) | −487 | $22.00 | -$10.7K | EDGAR |
| 2026-07-06 | FRANCIS LO | Chief People Officer | Mixed | −20,221 | $16.44 | -$1.50M | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Viking Long Fund Master Ltd. | 10%+ Owner | 38,406,607 | $1.13B | $35.00M | 1 | 2019-07-02 |
| 2 | Viking Global Opportunities GP LLC | 10%+ Owner | 36,108,295 | $1.06B | $35.00M | 1 | 2019-07-02 |
| 3 | Viking Global Equities II LP | 10%+ Owner | 33,493,708 | $983.54M | -$981.65M | 1 | 2020-01-30 |
| 4 | Viking Global Opportunities Illiquid Investments Sub-Master LP | 10%+ Owner | 33,493,708 | $983.54M | -$858.94M | 1 | 2020-01-30 |
| 5 | OLE ANDREAS HALVORSEN | 10%+ Owner | 30,993,708 | $910.13M | -$990.30M | 1 | 2020-11-13 |
| 6 | VIKING GLOBAL INVESTORS LP | 10%+ Owner | 29,993,708 | $880.77M | -$1.37B | 2 | 2020-12-16 |
| 7 | DAVID E. GOEL | Director | 13,116,594 | $385.17M | -$160.00M | 4 | 2021-02-17 |
| 8 | Matrix Capital Management Company, LP | Director | 12,702,505 | $373.01M | -$64.46M | 2 | 2021-03-10 |
| 9 | ANDRIS A ZOLTNERS | Director | 3,966,016 | $116.46M | -$9.14M | 3 | 2020-02-18 |
| 10 | CHAD M ROBINS | CEO and Chairman | 2,683,043 | $78.79M | -$88.62M | 43 | 2026-08-19 |
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-16 | FRANCIS LO | Officer | 142,198 | $3.79M | 2026-09-16 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-15 | SUSAN BOBULSKY | Officer | 1,195 | $29.6K | 2026-09-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-26 | KATHERINE E OWEN | Director | 9,615 | $250.0K | 2026-08-26 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-20 | Harlan Robins | Former Officer | 402,160 | $10.23M | 2026-08-20 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-08-19 | Harlan Robins | Former Officer | 215,632 | $5.50M | 2026-08-19 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-08-18 | Chad Robins | Officer | 278,676 | $6.84M | 2026-08-18 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-08-18 | Harlan Robins | Former Officer | 261,044 | $6.41M | 2026-08-18 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-08-18 | ROBERT M HERSHBERG | Director | 30,664 | $748.3K | 2026-08-18 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-17 | Harlan Robins | Former Officer | 300,992 | $7.46M | 2026-08-17 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-08-17 | Chad Robins | Officer | 321,324 | $7.96M | 2026-08-17 | Goldman Sachs & Co. LLC | — | EDGAR |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 31.1 |
| P/S Ratio | 14.4 |
| EV/EBITDA | -216.4 |
| TTM Revenue | $0.3B |
| TTM Net Income | $-0.1B |
| TTM EPS | $-0.41 |
| ROE | -44.7% |
| Debt/Equity | 2.34 |